Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

STAAR Surgical To Present At Upcoming Investor Conferences

STAA

~Stephens Fall Investment Conference on November 13 ~~CanaccordGenuity Medical Technology & Diagnostics Forum on November 14

MONROVIA, Calif., Nov. 5, 2013 /PRNewswire/ -- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced that it will participate in two upcoming investor conferences to review the Company's recent financial results and business developments with investors and interested parties.

Barry Caldwell, President and CEO, and Steve Brown, CFO, will present at the Stephens Fall Investment Conference at the New York Palace Hotel on Wednesday, November 13 at 9:00 a.m. ET.

The Company will also participate in a fireside chat at the CanaccordGenuity Medical Technology & Diagnostics Forum in New York at the Westin Grand Central on Thursday, November 14, 2013 at 9:00 a.m. ET. 

STAAR will offer live webcasts of both these events on the Company's website, www.staar.com, under Investor Information. The Stephens presentation will include audio with slides. The CanaccordGenuity fireside format provides audio only. An archived replay of the both these events will be available for 90 days, also at www.staar.com.

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 25 years, designs, develops, manufactures and markets implantable lenses for the eye and delivery systems therefor. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery as an alternative to LASIK is called an Implantable Collamer® Lens or "ICL." A lens used to replace the natural lens after cataract surgery is called an intraocular lens or "IOL." Over 375,000 Visian ICLs have been implanted to date; to learn more about the ICL go to: www.visianinfo.com. STAAR has approximately 300 full time employees and markets lenses in over 60 countries. Headquartered in Monrovia, CA, it manufactures in the following locations: Nidau, Switzerland; Aliso Viejo, CA; and Monrovia, CA. For more information, please visit the Company's website at www.staar.com

Collamer® is the registered trademark for STAAR's proprietary biocompatible collagen copolymer lens material. 

 

CONTACT:

Investors                  

Media


EVC Group

EVC Group


Doug Sherk, 415-652-9100 

Janine McCargo


Leigh Salvo, 415-568-9348   

646-688-0425             

SOURCE STAAR Surgical Company



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today